Zealand initiates obesity study together with Boehringer
Zealand Pharma and Boehringer Ingelheim have now chosen a biological target under their 2014 collaboration agreement. The companies aim to develop a candidate drug against obesity and expect to start a phase I study this year.
BY MARTIN HAVTORN PETERSEN
In 2014, the Danish biotech company Zealand Pharma signed a partnership deal with the German drug group Boehringer Ingelheim for the development of a peptide-based drug. Back then, information about disease areas and biological targets was scanty but now the biotech reveals the purpose of the collaboration.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand and Boehringer approach the clinic
For abonnenter
Analyst: Zealand drug faces hard time as monotherapy
For abonnenter
